Fig. 6: Pre-existing anti-replicase immunity does not affect the protection efficacy of a saRNAHA vaccine against a lethal H5N1 challenge.
From: Impact of pre-existing anti-replicase immunity on the efficacy of self-amplifying mRNA vaccines
a Schematic representation of the experimental setup. Anti-replicase immunity was induced in BALB/cJRj mice (n = 5) by two intramuscular injections of PBS (group A, black open circles; C, green solid upward triangles; and E, blue filled diamonds), 4 µg saRNAFluc-LNPs (group B, purple filled squares; and D, yellow solid downward triangles) or 1 µg saRNAFluc-LNPs (group F, red open circles) given 3 weeks apart. Two weeks after the last saRNAFluc-LNP injection, the mice in groups B, C and F were vaccinated twice with 1 µg of saRNAHA-RG-LNPs, with a three-week interval between doses. The mice in groups D and E were vaccinated with a single dose of 1 µg saRNAHA-RG-LNPs. Mice in group A were not vaccinated. Two weeks after the final saRNAHA-RG-LNP injection, blood was collected to determine HI titers and all mice were challenged with 5 LD50 NIBRG14. b HI titers (n = 5) in serum samples collected 2 weeks after the last saRNAHA-RG-LNP injection. The HI detection limit was 20 and is indicated as a dashed line, and titers below this threshold are shown as 1. c Mice body weight change after virus challenge (n = 5). d The survival rate after challenge (n = 5). Data are presented as geometric mean with geometric SD (b) or mean ± standard deviation (c). Statistical analysis was performed using Gehan-Breslow-Wilcoxon test (d). All samples are biological replicates. Exact P values are indicated above the comparison bars in the figure. All tests were two-sided. The schematic elements in (a) were created with BioRender.com. Source data are provided as a Source Data file.
